Research on low dosage naltrexone (Abstract)

Research on low dosage naltrexone

Tidsskr Nor Laegeforen
01 July 2011

Immunological research has provided new insight into the disease mechanism in multiple sclerosis and other immunological diseases and identified points of attack for, among other things, monoclonal antibodies. New preparations will necessarily be expensive, partly because large expenses for research will have to be earned. Prioritizing public research resources based on the price of the substance is a blind spot. A clinically randomized study of low-dose naltrexone will necessarily be costly, even if it is publicly funded. How reasonable will the treatment really be then?